Simtuzumab

Drug Profile

Simtuzumab

Alternative Names: AB-0024; Anti-LOXL2 monoclonal antibody; GS-6624

Latest Information Update: 26 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Arresto Biosciences
  • Developer Gilead Sciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Chemokine CXCL12 inhibitors; Connective tissue growth factor inhibitors; LOXL2 protein-inhibitors; Transforming growth factor beta1 inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatic fibrosis; Liver cirrhosis; Non-alcoholic steatohepatitis; Primary sclerosing cholangitis
  • Discontinued Colorectal cancer; Idiopathic pulmonary fibrosis; Myelofibrosis; Pancreatic cancer

Most Recent Events

  • 20 Apr 2017 Interim efficacy data from a phase IIb trial in Non-alcoholic steatohepatitis released by Gilead Sciences
  • 19 Apr 2017 Efficacy and safety data from phase IIb trial in Primary sclerosing cholangitis presented at The International Liver Congress 2017 (ILC-2017)
  • 19 Apr 2017 Efficacy and safety data from two phase IIb trial in Nonalcoholic steatohepatitis and Cirrhosis presented at The International Liver Congress 2017 (ILC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top